Acute renal failure secondary to oxalosis in a recipient of a simultaneous kidney-pancreas transplant: was mycophenolate the cause?
Open Access
- 9 April 2008
- journal article
- case report
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 23 (7) , 2409-2411
Abstract
Mycophenolate mofetil (MMF) is now the preferred antimetabolite for post-transplant immunosuppression [ 1]. Although leucopenia and diarrhoea are the main side effects, there are case reports of a malabsorption syndrome caused by MMF [ 2].Keywords
This publication has 7 references indexed in Scilit:
- Immunosuppressive Strategies to Improve Outcomes of Kidney TransplantationSeminars in Nephrology, 2007
- Drug Insight: maintenance immunosuppression in kidney transplant recipientsNature Clinical Practice Nephrology, 2006
- EARLY ALLOGRAFT FAILURE IN AN UNRECOGNIZED CASE OF PRIMARY HYPEROXALOSISNephrology, 2005
- Villous atrophy induced by mycophenolate mofetil in renal-transplant patientsTransplant International, 2004
- Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretionKidney International, 2004
- Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrheaTransplantation, 2003
- INTESTINAL MICROSPORIDIOSIS OCCURRING IN TWO RENAL TRANSPLANT RECIPIENTS TREATED WITH MYCOPHENOLATE MOFETILTransplantation, 1999